1
|
Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, Greene ER, Gus-Brautbar Y, Piwowarski J, Mammoto T, Zurakowski D, Perretti M, Sukhatme VP, Kaipainen A, Kieran MW, Huang S, Panigrahy D. Addendum: Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 2024; 221:e2017068101232024a. [PMID: 38294489 PMCID: PMC10829511 DOI: 10.1084/jem.2017068101232024a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024] Open
|
2
|
Zhu B, Wu H, Li KS, Eisa-Beygi S, Singh B, Bielenberg DR, Huang W, Chen H. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascul Pharmacol 2024; 154:107249. [PMID: 38070759 DOI: 10.1016/j.vph.2023.107249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 11/20/2023] [Accepted: 11/25/2023] [Indexed: 02/03/2024]
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis remain high, which is primarily due to widespread adoption of a western diet and sedentary lifestyle. NAFLD, together with advanced forms of this disease such as non-alcoholic steatohepatitis (NASH) and cirrhosis, are closely associated with atherosclerotic-cardiovascular disease (ASCVD). In this review, we discussed the association between NAFLD and atherosclerosis and expounded on the common molecular biomarkers underpinning the pathogenesis of both NAFLD and atherosclerosis. Furthermore, we have summarized the mode of function and potential clinical utility of existing drugs in the context of these diseases.
Collapse
Affiliation(s)
- Bo Zhu
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Hao Wu
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Kathryn S Li
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Shahram Eisa-Beygi
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Bandana Singh
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America
| | - Wendong Huang
- Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolic Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, United States of America
| | - Hong Chen
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America.
| |
Collapse
|
3
|
Lee E, Chan SL, Lee Y, Polacheck WJ, Kwak S, Wen A, Nguyen DHT, Kutys ML, Alimperti S, Kolarzyk AM, Kwak TJ, Eyckmans J, Bielenberg DR, Chen H, Chen CS. A 3D biomimetic model of lymphatics reveals cell-cell junction tightening and lymphedema via a cytokine-induced ROCK2/JAM-A complex. Proc Natl Acad Sci U S A 2023; 120:e2308941120. [PMID: 37782785 PMCID: PMC10576061 DOI: 10.1073/pnas.2308941120] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 09/04/2023] [Indexed: 10/04/2023] Open
Abstract
Impaired lymphatic drainage and lymphedema are major morbidities whose mechanisms have remained obscure. To study lymphatic drainage and its impairment, we engineered a microfluidic culture model of lymphatic vessels draining interstitial fluid. This lymphatic drainage-on-chip revealed that inflammatory cytokines that are known to disrupt blood vessel junctions instead tightened lymphatic cell-cell junctions and impeded lymphatic drainage. This opposing response was further demonstrated when inhibition of rho-associated protein kinase (ROCK) was found to normalize fluid drainage under cytokine challenge by simultaneously loosening lymphatic junctions and tightening blood vessel junctions. Studies also revealed a previously undescribed shift in ROCK isoforms in lymphatic endothelial cells, wherein a ROCK2/junctional adhesion molecule-A (JAM-A) complex emerges that is responsible for the cytokine-induced lymphatic junction zippering. To validate these in vitro findings, we further demonstrated in a genetic mouse model that lymphatic-specific knockout of ROCK2 reversed lymphedema in vivo. These studies provide a unique platform to generate interstitial fluid pressure and measure the drainage of interstitial fluid into lymphatics and reveal a previously unappreciated ROCK2-mediated mechanism in regulating lymphatic drainage.
Collapse
Affiliation(s)
- Esak Lee
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
- Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY14853
| | - Siu-Lung Chan
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - Yang Lee
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - William J. Polacheck
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| | - Sukyoung Kwak
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - Aiyun Wen
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - Duc-Huy T. Nguyen
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| | - Matthew L. Kutys
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| | - Stella Alimperti
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| | - Anna M. Kolarzyk
- Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY14853
| | - Tae Joon Kwak
- Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY14853
| | - Jeroen Eyckmans
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| | - Diane R. Bielenberg
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - Hong Chen
- Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA02115
| | - Christopher S. Chen
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA02115
- Department of Biomedical Engineering, Biological Design Center, Boston University, Boston, MA02215
| |
Collapse
|
4
|
Kipper FC, Rothenberger E, Kelly A, Gillespie M, Attaya A, Bielenberg DR, Huang S, Pflieger L, Sciavolino F, Mathias A, Klohs W, Parkinson J, Mathias G, Panigrahy D. Abstract 1135: TP317, a first-in-class resolvin E1 small molecule, potentiates the efficacy of immune checkpoint (ICI) inhibitors in ICI-resistant and ICI-sensitive tumors. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-1135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: TP317 is a novel, highly stable chelate salt of resolvin E1 (RvE1), a pro-resolution mediator that stimulates myeloid cell phagocytosis of tumor debris and attenuates pro-tumoral inflammation through activation of the GPCR, ChemR23 (Sulciner et al., 2018, J. Exp. Med). We hypothesized that RvE1 shifts the immunosuppressive tumor microenvironment (TME) to an immunogenic state, thus offering combination potential with immune checkpoint inhibitors (ICI) in ICI-resistant and ICI-sensitive tumors.
Methods: Subcutaneous murine models of lung (LLC), melanoma (B16F10), and pancreatic (Panc02; KPC) tumors were used to investigate TP-317 monotherapy and combinations with ICI. Treatment was initiated when tumors reached 125-240 mm3.
Results: In the LLC model (N=5/group), TP317 (0.75 µg QD) inhibited tumor growth (1419 ± 266 mm3) compared to placebo (2348 ± 542 mm3; p=0.068) and anti-PD1 (200 µg IP, Q3D; 3015 ± 730; p=0.078). TP317 + anti-PD1 dual therapy was superior to placebo and anti-PD1 alone (893 ± 166 mm3; p<0.05). In the B16F10 model (N=8/group), TP317 (7.5 µg Q6D) was efficacious compared to placebo (787 ± 367 vs 1964 ± 208 mm3; p<0.01) and comparable to the ICI dual therapy of anti-PD1 + anti-CTLA4 (100 µg 1st dose, 200 µg IP Q3D up to 4 doses). Triple therapy with TP317 + anti-PD1 + anti-CTLA4 was superior to ICI dual therapy (340 ± 91 vs 757 ± 260 mm3; p<0.05). In the Panc02 model (N=8/group), TP317 (0.75 µg Q7D) was efficacious compared to placebo (1148 ± 178 vs 1992 ±165 mm3; p<0.001) and comparable to anti-PD1. TP317 + anti-PD1 dual therapy demonstrated significant anti-tumor activity compared to anti-PD1 alone (329 ± 72 vs 1446 ± 305 mm3; p<0.01). In KRAS-mutant KPC tumors (N=10/group), TP317 (7.5 µg Q6D) demonstrated significant anti-tumor activity compared to placebo (500 ± 110 vs 1314 ± 106 mm3; p<0.001) and was comparable to anti-PD1, while TP-317 + anti-PD1 was superior to anti-PD1 alone (353 ± 82 vs 710 ± 106 mm3; p<0.01). In Panc02 and KPC models, TP317’s anti-tumor efficacy was attenuated by CD8+ T cell or NK cell depletion. Consistent with the depletion study results, RNAseq analysis with cell-type deconvolution showed that TP317 enhanced CD8 and NK cell associated programs in Panc02 and B16F10 tumors, and also promoted macrophage, dendritic cell, B cell and antigen presentation functions in the TME.
Conclusions: TP317 monotherapy and ICI combinations significantly inhibited tumor growth in various murine models of cancer. The effects on various immune cell functions and the surprising efficacy of short half-life RvE1 (<2 hours) dosed weekly suggests that TP317 is reprogramming the TME to an immunogenic state. In summary, TP317, an RvE1 drug with a high therapeutic index, has potent single agent efficacy and offers a novel approach in combination with ICI to treat ICI-resistant and ICI-sensitive tumors.
Citation Format: Franciele C. Kipper, Eva Rothenberger, Abigail Kelly, Michael Gillespie, Ahmed Attaya, Diane R. Bielenberg, Sui Huang, Lance Pflieger, Frank Sciavolino, Aaron Mathias, Wayne Klohs, John Parkinson, Gary Mathias, Dipak Panigrahy. TP317, a first-in-class resolvin E1 small molecule, potentiates the efficacy of immune checkpoint (ICI) inhibitors in ICI-resistant and ICI-sensitive tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1135.
Collapse
Affiliation(s)
| | - Eva Rothenberger
- 1Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
| | - Abigail Kelly
- 1Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
| | - Michael Gillespie
- 1Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
| | - Ahmed Attaya
- 1Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
| | | | - Sui Huang
- 3Institute of Systems Biology, Seattle, WA
| | - Lance Pflieger
- 4Institute of Systems Biology & Phenome Health, Seattle, WA
| | | | | | | | | | | | - Dipak Panigrahy
- 1Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
| |
Collapse
|
5
|
Liu X, Cui K, Wu H, Li KS, Peng Q, Wang D, Cowan DB, Dixon JB, Srinivasan RS, Bielenberg DR, Chen K, Wang DZ, Chen Y, Chen H. Promoting Lymphangiogenesis and Lymphatic Growth and Remodeling to Treat Cardiovascular and Metabolic Diseases. Arterioscler Thromb Vasc Biol 2023; 43:e1-e10. [PMID: 36453280 PMCID: PMC9780193 DOI: 10.1161/atvbaha.122.318406] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 11/15/2022] [Indexed: 12/03/2022]
Abstract
Lymphatic vessels are low-pressure, blind-ended tubular structures that play a crucial role in the maintenance of tissue fluid homeostasis, immune cell trafficking, and dietary lipid uptake and transport. Emerging research has indicated that the promotion of lymphatic vascular growth, remodeling, and function can reduce inflammation and diminish disease severity in several pathophysiologic conditions. In particular, recent groundbreaking studies have shown that lymphangiogenesis, which describes the formation of new lymphatic vessels from the existing lymphatic vasculature, can be beneficial for the alleviation and resolution of metabolic and cardiovascular diseases. Therefore, promoting lymphangiogenesis represents a promising therapeutic approach. This brief review summarizes the most recent findings related to the modulation of lymphatic function to treat metabolic and cardiovascular diseases such as obesity, myocardial infarction, atherosclerosis, and hypertension. We also discuss experimental and therapeutic approaches to enforce lymphatic growth and remodeling as well as efforts to define the molecular and cellular mechanisms underlying these processes.
Collapse
Affiliation(s)
- Xiaolei Liu
- Lemole Center for Integrated Lymphatics Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
| | - Kui Cui
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Hao Wu
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Kathryn S. Li
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Qianman Peng
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Donghai Wang
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Douglas B. Cowan
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - J. Brandon Dixon
- George W. Woodruff School of Mechanical Engineering, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA
| | - R. Sathish Srinivasan
- Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
| | - Diane R. Bielenberg
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| | - Kaifu Chen
- Department of Cardiology, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA
| | - Da-Zhi Wang
- USF Heart Institute, Center for Regenerative Medicine, College of Medicine Internal Medicine, University of South Florida, Tampa, FL
| | - Yabing Chen
- Department of Pathology, Birmingham Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, AL
| | - Hong Chen
- Vascular Biology Program, Department of Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
6
|
Lambrinos G, Cristofaro V, Pelton K, Bigger-Allen A, Doyle C, Vasquez E, Bielenberg DR, Sullivan MP, Adam RM. Neuropilin 2 Is a Novel Regulator of Distal Colon Contractility. Am J Pathol 2022; 192:1592-1603. [PMID: 35985479 PMCID: PMC9667714 DOI: 10.1016/j.ajpath.2022.07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 06/20/2022] [Accepted: 07/25/2022] [Indexed: 06/05/2023]
Abstract
Appropriate coordination of smooth muscle contraction and relaxation is essential for normal colonic motility. The impact of perturbed motility ranges from moderate, in conditions such as colitis, to potentially fatal in the case of pseudo-obstruction. The mechanisms underlying aberrant motility and the extent to which they can be targeted pharmacologically are incompletely understood. This study identified colonic smooth muscle as a major site of expression of neuropilin 2 (Nrp2) in mice and humans. Mice with inducible smooth muscle-specific knockout of Nrp2 had an increase in evoked contraction of colonic rings in response to carbachol at 1 and 4 weeks following initiation of deletion. KCl-induced contractions were also increased at 4 weeks. Colonic motility was similarly enhanced, as evidenced by faster bead expulsion in Nrp2-deleted mice versus Nrp2-intact controls. In length-tension analysis of the distal colon, passive tension was similar in Nrp2-deficient and Nrp2-intact mice, but at low strains, active stiffness was greater in Nrp2-deficient animals. Consistent with the findings in conditional Nrp2 mice, Nrp2-null mice showed increased contractility in response to carbachol and KCl. Evaluation of selected proteins implicated in smooth muscle contraction revealed no significant differences in the level of α-smooth muscle actin, myosin light chain, calponin, or RhoA. Together, these findings identify Nrp2 as a novel regulator of colonic contractility that may be targetable in conditions characterized by dysmotility.
Collapse
Affiliation(s)
- George Lambrinos
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts
| | - Vivian Cristofaro
- Department of Surgery, Harvard Medical School, Boston, Massachusetts; Division of Urology, VA Boston Healthcare System, Boston, Massachusetts
| | - Kristine Pelton
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts
| | - Alexander Bigger-Allen
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts; Biological and Biomedical Sciences Program, Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts
| | - Claire Doyle
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts
| | - Evalynn Vasquez
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts
| | - Diane R Bielenberg
- Department of Surgery, Harvard Medical School, Boston, Massachusetts; Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts
| | - Maryrose P Sullivan
- Department of Surgery, Harvard Medical School, Boston, Massachusetts; Division of Urology, VA Boston Healthcare System, Boston, Massachusetts.
| | - Rosalyn M Adam
- Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
7
|
Alfaris S, Almazyad A, Omari J, Gao Y, Balasubbramanian D, Bielenberg DR. Deletion of Neuropilin‐1 in the Epidermis Delays Wound Healing. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Sausan Alfaris
- Vascular Biology ProgramBoston Children's HospitalBOSTONMA
- Department of Oral Medicine, Infection, and ImmunityHarvard School of Dental MedicineBostonMA
| | - Asma Almazyad
- Department of Oral Medicine, Infection, and ImmunityHarvard School of Dental MedicineBostonMA
- Vascular Biology ProgramBoston Children's HospitalBostonMA
| | - Joud Omari
- Vascular Biology ProgramBoston Children's HospitalBOSTONMA
- Department of Oral Medicine, Infection, and ImmunityHarvard School of Dental MedicineBostonMA
| | - Yao Gao
- Vascular Biology ProgramBoston Children's HospitalBOSTONMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | | | - Diane R. Bielenberg
- Vascular Biology ProgramBoston Children's HospitalBOSTONMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| |
Collapse
|
8
|
Omari J, Almazyad A, Alfaris S, Balasubbramanian D, Colombo D, Gao Y, Bielenberg DR. Semaphorin‐3F Deletion Prevents Oral Carcinogenesis. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r4052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Joud Omari
- Vascular biologyBoston Children's HospitalBostonMA
- Department of Oral Medicine, Infection, and ImmunityBoston Children's HospitalBostonMA
| | - Asma Almazyad
- Vascular biologyBoston Children's HospitalBostonMA
- Department of Oral Medicine, Infection, and ImmunityBoston Children's HospitalBostonMA
| | - Sausan Alfaris
- Vascular biologyBoston Children's HospitalBostonMA
- Department of Oral Medicine, Infection, and ImmunityBoston Children's HospitalBostonMA
| | | | - Dan Colombo
- Vascular biologyBoston Children's HospitalBostonMA
| | - Yao Gao
- Vascular biologyBoston Children's HospitalBostonMA
- Department of SurgeryBoston Children's HospitalBostonMA
| | - Diane R. Bielenberg
- Department of SurgeryBoston Children's HospitalBostonMA
- Vascular Biology ProgramBoston Children's HospitalBostonMA
| |
Collapse
|
9
|
Rothenberger E, Wang W, Kipper FC, Kelly A, Hwang SH, Duncan M, Bielenberg DR, Henderson PT, Cimino G, Zimmermann M, Hammock BD, Panigrahy D. Dual COX‐2/sEH Inhibition and Immune Checkpoint Blockade Regress Bladder Cancer Tumors in Mice. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Eva Rothenberger
- Department of Pathology and Center for Vascular Biology ResearchBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonMA
| | | | - Franciele C. Kipper
- Department of Pathology and Center for Vascular Biology ResearchBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonMA
| | - Abigail Kelly
- Department of Pathology and Center for Vascular Biology ResearchBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonMA
| | | | - Madeline Duncan
- Department of Pathology and Center for Vascular Biology ResearchBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonMA
| | | | | | | | | | | | - Dipak Panigrahy
- Department of Pathology and Center for Vascular Biology ResearchBeth Israel Deaconess Medical Center and Harvard Medical SchoolBostonMA
| |
Collapse
|
10
|
Balasubbramanian D, Lambrinos G, Cristofaro V, Bigger‐Allen A, Wang B, Gao Y, Chen H, Adam RM, Sullivan MP, Bielenberg DR. Smooth Muscle‐Specific Deletion of Neuropilin‐1 Increases Vascular Contractility and Blood Pressure. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r4956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - George Lambrinos
- SurgeryHarvard Medical SchoolBostonMA
- Urology ResearchBoston Children's HospitalBostonMA
| | - Vivian Cristofaro
- SurgeryHarvard Medical SchoolBostonMA
- Veteran Affairs Boston Healthcare SystemBostonMA
| | | | - Beibei Wang
- SurgeryHarvard Medical SchoolBostonMA
- Boston Children's HospitalBostonMA
| | - Yao Gao
- Vascular Biology ProgramBoston Children's HospitalBostonMA
- SurgeryHarvard Medical SchoolBostonMA
| | - Hong Chen
- SurgeryHarvard Medical SchoolBostonMA
- Boston Children's HospitalBostonMA
| | - Rosalyn M. Adam
- SurgeryHarvard Medical SchoolBostonMA
- Boston Children's HospitalBostonMA
| | - Maryrose P. Sullivan
- SurgeryHarvard Medical SchoolBostonMA
- Veteran Affairs Boston Healthcare SystemBostonMA
| | | |
Collapse
|
11
|
Wu H, Norton V, Cui K, Zhu B, Bhattacharjee S, Lu YW, Wang B, Shan D, Wong S, Dong Y, Chan SL, Cowan D, Xu J, Bielenberg DR, Zhou C, Chen H. Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses. Front Cardiovasc Med 2022; 9:841928. [PMID: 35252405 PMCID: PMC8891533 DOI: 10.3389/fcvm.2022.841928] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 01/18/2022] [Indexed: 12/12/2022] Open
Abstract
Diabetes mellitus is a worldwide health problem that usually comes with severe complications. There is no cure for diabetes yet and the threat of these complications is what keeps researchers investigating mechanisms and treatments for diabetes mellitus. Due to advancements in genomics, epigenomics, proteomics, and single-cell multiomics research, considerable progress has been made toward understanding the mechanisms of diabetes mellitus. In addition, investigation of the association between diabetes and other physiological systems revealed potentially novel pathways and targets involved in the initiation and progress of diabetes. This review focuses on current advancements in studying the mechanisms of diabetes by using genomic, epigenomic, proteomic, and single-cell multiomic analysis methods. It will also focus on recent findings pertaining to the relationship between diabetes and other biological processes, and new findings on the contribution of diabetes to several pathological conditions.
Collapse
Affiliation(s)
- Hao Wu
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Vikram Norton
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Kui Cui
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Bo Zhu
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Sudarshan Bhattacharjee
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Yao Wei Lu
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Beibei Wang
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Dan Shan
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Scott Wong
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Yunzhou Dong
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Siu-Lung Chan
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Douglas Cowan
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Jian Xu
- Department of Medicine, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, United States
| | - Diane R. Bielenberg
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
| | - Changcheng Zhou
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States
| | - Hong Chen
- Department of Surgery, Vascular Biology Program, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States
- *Correspondence: Hong Chen
| |
Collapse
|
12
|
Song K, Cai X, Dong Y, Wu H, Wei Y, Shankavaram UT, Cui K, Lee Y, Zhu B, Bhattacharjee S, Wang B, Zhang K, Wen A, Wong S, Yu L, Xia L, Welm AL, Bielenberg DR, Camphausen KA, Kang Y, Chen H. Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development. J Clin Invest 2021; 131:129374. [PMID: 32960814 DOI: 10.1172/jci129374] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Accepted: 09/17/2020] [Indexed: 12/14/2022] Open
Abstract
Estrogen receptor-negative (ER-negative) breast cancer is thought to be more malignant and devastating than ER-positive breast cancer. ER-negative breast cancer exhibits elevated NF-κB activity, but how this abnormally high NF-κB activity is maintained is poorly understood. The importance of linear ubiquitination, which is generated by the linear ubiquitin chain assembly complex (LUBAC), is increasingly appreciated in NF-κB signaling, which regulates cell activation and death. Here, we showed that epsin proteins, a family of ubiquitin-binding endocytic adaptors, interacted with LUBAC via its ubiquitin-interacting motif and bound LUBAC's bona fide substrate NEMO via its N-terminal homolog (ENTH) domain. Furthermore, epsins promoted NF-κB essential modulator (NEMO) linear ubiquitination and served as scaffolds for recruiting other components of the IκB kinase (IKK) complex, resulting in the heightened IKK activation and sustained NF-κB signaling essential for the development of ER-negative breast cancer. Heightened epsin levels in ER-negative human breast cancer are associated with poor relapse-free survival. We showed that transgenic and pharmacological approaches eliminating epsins potently impeded breast cancer development in both spontaneous and patient-derived xenograft breast cancer mouse models. Our findings established the pivotal role epsins played in promoting breast cancer. Thus, targeting epsins may represent a strategy to restrain NF-κB signaling and provide an important perspective into ER-negative breast cancer treatment.
Collapse
Affiliation(s)
- Kai Song
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Xiaofeng Cai
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.,Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Yunzhou Dong
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Hao Wu
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Yong Wei
- Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.,Cancer Metabolism and Growth Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Uma T Shankavaram
- Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
| | - Kui Cui
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Yang Lee
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Bo Zhu
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Sudarshan Bhattacharjee
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Beibei Wang
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Kun Zhang
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Aiyun Wen
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Scott Wong
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Lili Yu
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Lijun Xia
- Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Alana L Welm
- Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Kevin A Camphausen
- Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
| | - Yibin Kang
- Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.,Cancer Metabolism and Growth Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Hong Chen
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
13
|
Balasubbramanian D, Lambrinos G, Cristofaro V, Bigger-Allen A, Wang B, Gao Y, Chen H, Adam RM, Sullivan MP, Bielenberg DR. Abstract MP17: Neuropilin-1 Is A Novel Regulator Of Vascular Tone And Blood Pressure. Hypertension 2021. [DOI: 10.1161/hyp.78.suppl_1.mp17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Neuropilin-1 (NRP1) is a transmembrane receptor present in vascular smooth muscle cells (VSMC) that mediates the inhibition of Rho signaling by binding the Class 3 Semaphorin (SEMA) ligand SEMA3A.
Hypothesis:
We hypothesize that loss of NRP1 in VSMC mitigates SEMA3A-induced Rho inhibition, thereby increasing vascular tone and blood pressure
in vivo
.
Methods:
Male and female adult mice (8-12 weeks) with inducible, smooth muscle cell-specific deletion of NRP1 (SM22a-Cre
ERT2
X Nrp1
flox/flox
) were examined. Following recombination using 4-hydroxy tamoxifen (SM-
NRP1
KO), systolic blood pressure (SBP) was measured using a tail cuff and compared to age- and sex-matched mice that did not receive tamoxifen (control). Aortic vascular reactivity and expression of key proteins in the Rho signaling cascade were measured using
ex vivo
tension myography and western blotting, respectively.
Results:
SBP was significantly increased in SM-
NRP1
KO mice following recombination compared to control mice (SBP: 136.5 ± 10.9 vs 112.9 ± 5.6 mmHg; p=0.0006). Contractile responses in aortas of SM-
NRP1
KO mice to phenylephrine (p=0.025), KCl (p=0.012), and the thromboxane agonist U44619 (p=0.019) were significantly enhanced compared to controls. Expression of total myosin light chain and LIMK-2 proteins were increased in SM-
NRP1
KO compared to control aortas.
In vitro
, treatment of murine primary VSMC expressing NRP1 with SEMA3A decreased angiotensin II-induced Rho-GTP activation. Additionally, control and SM-
NRP1
KO mice (starting at 2 weeks post-recombination) were administered angiotensin II (490 ng/kg/day) for 4 weeks. While there was no significant difference in SBP at weeks 1 and 2, SM-
NRP1
KO mice had significantly lower SBP at weeks 3 and 4 following angiotensin II infusion compared to controls (Week 4 SBP: 150 ± 1.4 vs 130.5 ± 2.5 mmHg; p=0.02), suggesting a low ejection fraction and cardiac dysfunction in these mice. In support of this observation, mRNA expression of atrial natriuretic peptide was increased in hearts of angiotensin II-infused SM-
NRP1
KO mice.
Conclusion:
Our data suggest that VSMC NRP1 regulates basal tone and blood pressure, and that loss of NRP1 causes hypertension and exacerbates cardiac dysfunction.
Collapse
Affiliation(s)
| | | | | | | | | | - Yao Gao
- Boston Children's Hosp, Boston, MA
| | | | | | | | | |
Collapse
|
14
|
Almazyad AM, Gao Y, Shahrabi-Farahani S, Gartung A, Sui L, Das R, Costea DE, Watnick RS, Panigrahy D, Adam RM, Bielenberg DR. NOVEL NEUROPILIN 2-TARGETING BIOLOGIC FOR THE TREATMENT OF ORAL SQUAMOUS CELL CARCINOMA. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Yu LJ, Ko VH, Dao DT, Secor JD, Pan A, Cho BS, Mitchell PD, Kishikawa H, Bielenberg DR, Puder M. Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain. Sci Rep 2021; 11:11827. [PMID: 34088930 PMCID: PMC8178332 DOI: 10.1038/s41598-021-91127-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 05/17/2021] [Indexed: 02/04/2023] Open
Abstract
Morbidity and mortality for neonates with congenital diaphragmatic hernia-associated pulmonary hypoplasia remains high. These patients may be deficient in vascular endothelial growth factor (VEGF). Our lab previously established that exogenous VEGF164 accelerates compensatory lung growth (CLG) after left pneumonectomy in a murine model. We aimed to further investigate VEGF-mediated CLG by examining the role of the heparin-binding domain (HBD). Eight-week-old, male, C57BL/6J mice underwent left pneumonectomy, followed by post-operative and daily intraperitoneal injections of equimolar VEGF164 or VEGF120, which lacks the HBD. Isovolumetric saline was used as a control. VEGF164 significantly increased lung volume, total lung capacity, and alveolarization, while VEGF120 did not. Treadmill exercise tolerance testing (TETT) demonstrated improved functional outcomes post-pneumonectomy with VEGF164 treatment. In lung protein analysis, VEGF treatment modulated downstream angiogenic signaling. Activation of epithelial growth factor receptor and pulmonary cell proliferation was also upregulated. Human microvascular lung endothelial cells (HMVEC-L) treated with VEGF demonstrated decreased potency of VEGFR2 activation with VEGF121 treatment compared to VEGF165 treatment. Taken together, these data indicate that the VEGF HBD contributes to angiogenic and proliferative signaling, is required for accelerated compensatory lung growth, and improves functional outcomes in a murine CLG model.
Collapse
Affiliation(s)
- Lumeng J. Yu
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Victoria H. Ko
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Duy T. Dao
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Jordan D. Secor
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Amy Pan
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Bennet S. Cho
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Paul D. Mitchell
- grid.2515.30000 0004 0378 8438Institutional Centers for Clinical and Translational Research, Boston Children’s Hospital, Boston, MA 02115 USA
| | - Hiroko Kishikawa
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| | - Diane R. Bielenberg
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| | - Mark Puder
- grid.2515.30000 0004 0378 8438Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115 USA ,grid.2515.30000 0004 0378 8438Department of Surgery, Boston Children’s Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA 02115 USA
| |
Collapse
|
16
|
Chung I, Zhou K, Barrows C, Banyard J, Wilson A, Rummel N, Mizokami A, Basu S, Sengupta P, Shaikh B, Sengupta S, Bielenberg DR, Zetter BR. Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer. Front Oncol 2021; 10:594141. [PMID: 33738243 PMCID: PMC7962607 DOI: 10.3389/fonc.2020.594141] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 12/30/2020] [Indexed: 01/06/2023] Open
Abstract
In American men, prostate cancer is the second leading cause of cancer-related death. Dissemination of prostate cancer cells to distant organs significantly worsens patients' prognosis, and currently there are no effective treatment options that can cure advanced-stage prostate cancer. In an effort to identify compounds selective for metastatic prostate cancer cells over benign prostate cancer cells or normal prostate epithelial cells, we applied a phenotype-based in vitro drug screening method utilizing multiple prostate cancer cell lines to test 1,120 different compounds from a commercial drug library. Top drug candidates were then examined in multiple mouse xenograft models including subcutaneous tumor growth, experimental lung metastasis, and experimental bone metastasis assays. A subset of compounds including fenbendazole, fluspirilene, clofazimine, niclosamide, and suloctidil showed preferential cytotoxicity and apoptosis towards metastatic prostate cancer cells in vitro and in vivo. The bioavailability of the most discerning agents, especially fenbendazole and albendazole, was improved by formulating as micelles or nanoparticles. The enhanced forms of fenbendazole and albendazole significantly prolonged survival in mice bearing metastases, and albendazole-treated mice displayed significantly longer median survival times than paclitaxel-treated mice. Importantly, these drugs effectively targeted taxane-resistant tumors and bone metastases - two common clinical conditions in patients with aggressive prostate cancer. In summary, we find that metastatic prostate tumor cells differ from benign prostate tumor cells in their sensitivity to certain drug classes. Taken together, our results strongly suggest that albendazole, an anthelmintic medication, may represent a potential adjuvant or neoadjuvant to standard therapy in the treatment of disseminated prostate cancer.
Collapse
Affiliation(s)
- Ivy Chung
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
- Department of Surgery, Harvard Medical School, Boston, MA, United States
| | - Kun Zhou
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
- Department of Surgery, Harvard Medical School, Boston, MA, United States
| | - Courtney Barrows
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
| | - Jacqueline Banyard
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
- Department of Surgery, Harvard Medical School, Boston, MA, United States
| | - Arianne Wilson
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
| | - Nathan Rummel
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Washington, DC, United States
| | - Atsushi Mizokami
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Sudipta Basu
- Laboratory for Nanomedicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States
| | - Poulomi Sengupta
- Laboratory for Nanomedicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States
| | - Badaruddin Shaikh
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Washington, DC, United States
| | - Shiladitya Sengupta
- Laboratory for Nanomedicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States
| | - Diane R. Bielenberg
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
- Department of Surgery, Harvard Medical School, Boston, MA, United States
| | - Bruce R. Zetter
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States
- Department of Surgery, Harvard Medical School, Boston, MA, United States
| |
Collapse
|
17
|
Yu LJ, Ko VH, Dao DT, Secor JD, Cho BS, Pan A, Bielenberg DR, Puder M. Vascular Endothelial Growth Factor Heparin-Binding Domain Contributes to Proliferative Signaling and Pulmonary Functional Outcomes in Compensatory Lung Growth. J Am Coll Surg 2020. [DOI: 10.1016/j.jamcollsurg.2020.07.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Amarnani D, Sanchez AV, Wong LL, Duffy BV, Ramos L, Freitag SK, Bielenberg DR, Kim LA, Lee NG. Characterization of a Murine Model of Oxazolone-Induced Orbital Inflammation. Transl Vis Sci Technol 2020; 9:26. [PMID: 32855872 PMCID: PMC7422768 DOI: 10.1167/tvst.9.8.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Accepted: 05/04/2020] [Indexed: 01/15/2023] Open
Abstract
Purpose Acute orbital inflammation can lead to irreversible vision loss in serious cases. Treatment thus far has been limited to systemic steroids or surgical decompression of the orbit. An animal model that mimics the characteristic features of acute orbital inflammation as found in thyroid eye disease can be used to explore novel treatment modalities. Methods We developed a murine model of orbital inflammation by injecting oxazolone into the mouse orbit. The mice underwent magnetic resonance imaging (MRI) and were euthanized at various time points for histologic examination. Immunofluorescence studies of specific inflammatory cells and cytokine arrays were performed. Results We found clinical and radiographic congruity between the murine model and human disease. After 72 hours, sensitized mice exhibited periorbital dermatitis and inflammation in the eyelids of the injected side. By one week, increased proptosis in the injected eye with significant eyelid edema was appreciated. By four weeks, inflammation and proptosis were decreased. At all three time points, the mice demonstrated exophthalmos and periorbital edema. Histopathologically, populations of inflammatory cells including T cells, macrophages, and neutrophils shared similarities with patient samples in thyroid eye disease. Proteomic changes in the levels of inflammatory and angiogenic markers correlated to the expected angiogenic, inflammatory, and fibrotic responses observed in patients with thyroid eye disease. Conclusions A murine model of orbital inflammation created using oxazolone recapitulates some of the clinical features of thyroid eye disease and potentially other nonspecific orbital inflammation, typified by inflammatory cell infiltration, orbital tissue expansion and remodeling, and subsequent fibrosis. Translational Relevance This animal model could serve as a viable platform with which to understand the underlying mechanisms of acute orbital inflammation and to investigate potential new, targeted treatments.
Collapse
Affiliation(s)
- Dhanesh Amarnani
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| | - Angie V Sanchez
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| | - Lindsay L Wong
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| | | | | | - Suzanne K Freitag
- Ophthalmic Plastic Surgery, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, USA
| | - Leo A Kim
- Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.,Retina Service, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| | - Nahyoung Grace Lee
- Ophthalmic Plastic Surgery, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
19
|
Atta H, Gheinani AH, Wacker A, Heshmati Y, Bigger-Allen A, Lambrinos G, Gao Y, Bielenberg DR, Adam RM. A Single Cell Dissociation Approach for Molecular Analysis of Urinary Bladder in the Mouse Following Spinal Cord Injury. J Vis Exp 2020. [PMID: 32628176 DOI: 10.3791/61455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
We describe the implementation of spinal cord injury in mice to elicit detrusor-sphincter dyssynergia, a functional bladder outlet obstruction, and subsequent bladder wall remodeling. To facilitate assessment of the cellular composition of the bladder wall in non-injured control and spinal cord injured mice, we developed an optimized dissociation protocol that supports high cell viability and enables the detection of discrete subpopulations by flow cytometry. Spinal cord injury is created by complete transection of the thoracic spinal cord. At the time of tissue harvest, the animal is perfused with phosphate-buffered saline under deep anesthesia and bladders are harvested into Tyrode's buffer. Tissues are minced prior to incubation in digestion buffer that has been optimized based on the collagen content of mouse bladder as determined by interrogation of publicly available gene expression databases. Following generation of a single cell suspension, material is analyzed by flow cytometry for assessment of cell viability, cell number and specific subpopulations. We demonstrate that the method yields cell populations with greater than 90% viability, and robust representation of cells of mesenchymal and epithelial origin. This method will enable accurate downstream analysis of discrete cell types in mouse bladder and potentially other organs.
Collapse
Affiliation(s)
- Hussein Atta
- Department of Urology, Boston Children's Hospital; Department of Surgery, Harvard Medical School
| | - Ali Hashemi Gheinani
- Department of Urology, Boston Children's Hospital; Department of Surgery, Harvard Medical School;
| | | | - Yaser Heshmati
- Division of Hematology/Oncology, Harvard Medical School Boston; Dana-Farber Cancer Institute; Broad Institute
| | - Alex Bigger-Allen
- Department of Urology, Boston Children's Hospital; Biological Biomedical Sciences Program, Division of Medical Sciences, Harvard Medical School
| | - George Lambrinos
- Department of Urology, Boston Children's Hospital; Department of Surgery, Harvard Medical School
| | - Yao Gao
- Department of Surgery, Harvard Medical School; Vascular Biology Program, Boston Children's Hospital
| | - Diane R Bielenberg
- Department of Surgery, Harvard Medical School; Vascular Biology Program, Boston Children's Hospital
| | - Rosalyn M Adam
- Department of Urology, Boston Children's Hospital; Department of Surgery, Harvard Medical School;
| |
Collapse
|
20
|
Hallisey VM, Kipper FC, Moore J, Gartung A, Bielenberg DR, Petrik J, Lawler J, Panigrahy D, Serhan CN. Pro‐Resolving Lipid Mediators and Anti‐Angiogenic Therapy Exhibit Synergistic Anti‐Tumor Activity via Resolvin Receptor Activation. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.05830] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
21
|
Colombo D, Das R, Almazyad A, Gao Y, Bielenberg DR. Tumor Growth in the Skin during Anagen and Telogen Phases of the Mouse Hair Cycle. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.07205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Dan Colombo
- Boston Children’s Hospital
- Dana-Farber/Harvard Cancer Center
| | - Ridhima Das
- Boston Children’s Hospital
- University of Bergen
| | - Asma Almazyad
- Boston Children’s Hospital
- Harvard School of Dental Medicine
| | - Yao Gao
- Boston Children’s Hospital
- Harvard Medical School
| | - Diane R. Bielenberg
- Boston Children’s Hospital
- Dana-Farber/Harvard Cancer Center
- Harvard Medical School
| |
Collapse
|
22
|
Gao Y, Lee Y, Almazyad A, Birsner A, Li D, Wong S, Wen A, D’Amato R, Adam RM, Dixon JB, Srinivasan RS, Chen H, Bielenberg DR. Loss of Neuropilin 2 in Adult Lymphatic Endothelium Promotes Lymphedema. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.06345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Yao Gao
- Boston Children’s Hospital
- Harvard Medical School
| | - Yang Lee
- Boston Children’s Hospital
- Harvard Medical School
| | - Asma Almazyad
- Boston Children’s Hospital
- Harvard School of Dental Medicine
| | | | | | | | | | | | | | | | | | - Hong Chen
- Boston Children’s Hospital
- Harvard Medical School
| | | |
Collapse
|
23
|
Fishbein A, Deng J, Hwang SH, Wang W, Yang J, Verheul S, Hallisey VM, Bielenberg DR, Gartung A, Hammock BD, Panigrahy D. Chemoprevention of Aflatoxin B1‐Induced Cytokine Storm and Tumor Dormancy Escape via Dual COX‐2/sEH Inhibition. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.05922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
24
|
Almazyad A, Gao Y, Shahrabi-Farahani S, Sui L, Gartung A, Das R, Costea DE, Watnick R, Panigrahy D, Adam RM, Bielenberg DR. Neuropilin 2 Drives Tumor Lymphangiogenesis in Oral Squamous Cell Carcinoma. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.02389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Asma Almazyad
- Boston Children’s Hospital
- Harvard School of Dental Medicine
| | - Yao Gao
- Boston Children’s Hospital
- Boston Children Hospital
| | | | - Lufei Sui
- Boston Children’s Hospital
- Harvard Medical School
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Almazyad A, Gao Y, Shahrabi-Farahani S, Sui L, Gartung A, Watnick R, Panigrahy D, Adam RM, Bielenberg DR. Semaphorin 3F: A Novel Biologic Treatment for Oral Squamous Cell Carcinoma. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.02668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Asma Almazyad
- Boston Children’s Hospital
- Harvard School of Dental Medicine
| | - Yao Gao
- Boston Children’s Hospital
- Harvard Medical School
| | | | - Lufei Sui
- Boston Children’s Hospital
- Harvard Medical School
| | | | | | | | | | | |
Collapse
|
26
|
Panigrahy D, Gartung A, Yang J, Yang H, Gilligan MM, Sulciner ML, Bhasin SS, Bielenberg DR, Chang J, Schmidt BA, Piwowarski J, Fishbein A, Soler-Ferran D, Sparks MA, Staffa SJ, Sukhatme V, Hammock BD, Kieran MW, Huang S, Bhasin M, Serhan CN, Sukhatme VP. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J Clin Invest 2019; 129:2964-2979. [PMID: 31205032 DOI: 10.1172/jci127282] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 04/17/2019] [Indexed: 12/14/2022] Open
Abstract
Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence. We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation. Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival. Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway. Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses. Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape. Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.
Collapse
Affiliation(s)
- Dipak Panigrahy
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Allison Gartung
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Jun Yang
- Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, California, USA
| | - Haixia Yang
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Molly M Gilligan
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Megan L Sulciner
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Swati S Bhasin
- Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | | | - Jaimie Chang
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Birgitta A Schmidt
- Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Julia Piwowarski
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Anna Fishbein
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Dulce Soler-Ferran
- Center for Vascular Biology Research.,Department of Pathology, and.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Matthew A Sparks
- Division of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA
| | - Steven J Staffa
- Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | - Bruce D Hammock
- Department of Entomology and Nematology, and UC Davis Comprehensive Cancer Center, University of California, Davis, California, USA
| | - Mark W Kieran
- Division of Pediatric Oncology, Dana-Farber Cancer Institute, and.,Department of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Sui Huang
- Institute for Systems Biology, Seattle, Washington, USA
| | - Manoj Bhasin
- Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Charles N Serhan
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Vikas P Sukhatme
- Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine and Center for Affordable Medical Innovation, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
27
|
Almazyad A, Shahrabi‐Farahani S, Gartung A, Panigraphy D, Bielenberg DR. Dual Expression of Neuropilin‐2 in Tumor and Stroma in Oral Dysplasia and Oral Squamous Cell Carcinoma. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.496.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Asma Almazyad
- Vascular Biology ProgramBoston Children's HospitalBostonMA
- Harvard School of Dental MedicineBostonMA
| | | | - Allison Gartung
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
- Department of PathologyHarvard Medical SchoolBostonMA
| | - Dipak Panigraphy
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
- Department of PathologyHarvard Medical SchoolBostonMA
| | - Diane R. Bielenberg
- Vascular Biology ProgramBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| |
Collapse
|
28
|
Destin O, Niclou B, Li X, Levonyak N, Jia A, Watnick RS, Adam RM, Bielenberg DR. Neovascularization in Pancreatic Cancer is Dependent on Neuropilin 2. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.120.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Orlane Destin
- Vascular Biology Program
- CURE ProgramDana‐Farber Harvard Cancer CenterBostonMA
| | | | | | | | | | - Randy S. Watnick
- Vascular Biology Program
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Rosalyn M. Adam
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | | |
Collapse
|
29
|
Hallisey V, Barksdale CA, Chang J, Sulciner ML, Bielenberg DR, Schmidt BA, Keiran N, Haung S, Serhan CN, Keiran MW, Panigrahy D. Brain Cancer: Failure of Resolution of Inflammation? FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.250.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Jaimie Chang
- PathologyBeth Israel Deaconess Medical CenterBostonMA
| | | | | | | | | | - Sui Haung
- Institute for Systems BiologySeattleWA
| | | | | | | |
Collapse
|
30
|
Niclou B, Li X, Zessler A, Jia A, Mahmood F, Briscoe DM, Watnick RS, Adam RM, Bielenberg DR. An Inhibitory Ligand of Neuropilin 2 Blocks Pancreatic Cancer Progression and Impedes Tumor Angiogenesis. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.368.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Xiaoran Li
- Vascular BiologyBoston Children's HospitalBostonMA
| | | | - Amy Jia
- Vascular BiologyBoston Children's HospitalBostonMA
| | - Fabliha Mahmood
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
| | - David M. Briscoe
- Transplant Research ProgramBoston Children's HospitalBostonMA
- Department of PediatricsHarvard Medical SchoolBostonMA
| | - Randolph S. Watnick
- Vascular BiologyBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Rosalyn M. Adam
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Diane R. Bielenberg
- Vascular BiologyBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| |
Collapse
|
31
|
Bielenberg DR, Doyle C, Vasquez E, Pelton K, Cristofaro V, Sullivan MP, Adam RM. Altered Gut Motility in Mice Lacking Neuropilin 2 in Smooth Muscle. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.496.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Diane R. Bielenberg
- Vascular Biology ProgramBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Claire Doyle
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Evalynn Vasquez
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| | - Kristine Pelton
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
| | - Vivian Cristofaro
- Department of SurgeryHarvard Medical SchoolBostonMA
- Urology ResearchVA Boston Healthcare SystemWest RoxburyMA
| | - Maryrose P. Sullivan
- Department of SurgeryHarvard Medical SchoolBostonMA
- Urology ResearchVA Boston Healthcare SystemWest RoxburyMA
| | - Rosalyn M. Adam
- Urological Diseases Research CenterBoston Children's HospitalBostonMA
- Department of SurgeryHarvard Medical SchoolBostonMA
| |
Collapse
|
32
|
Gartung A, Gilligan MM, Bielenberg DR, Fishbein A, Wells S, Huang S, Kieran MW, Serhan CN, Panigrahy D. Synergy between Resolvins and Immune Checkpoint Blockade in a Novel Transplantable
FANCC
−/−
Murine Head and Neck Tumor Model. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.496.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Allison Gartung
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
| | - Molly M. Gilligan
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
| | | | - Anna Fishbein
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
| | - Susanne Wells
- Department of OncologyCincinnati Children's Hospital Medical CenterCincinnatiOH
| | - Sui Huang
- Institute for Systems BiologySeattleWA
| | - Mark W. Kieran
- Division of Pediatric OncologyDana‐Farber Cancer InstituteBostonMA
| | - Charles N. Serhan
- Center for Experimental Therapeutics and Reperfusion InjuryBrigham and Women's HospitalBostonMA
| | - Dipak Panigrahy
- Center for Vascular Biology ResearchBeth Israel Deaconess Medical CenterBostonMA
| |
Collapse
|
33
|
Dao DT, Anez-Bustillos L, Jabbouri SS, Pan A, Kishikawa H, Mitchell PD, Fell GL, Baker MA, Watnick RS, Chen H, Rogers MS, Bielenberg DR, Puder M. A paradoxical method to enhance compensatory lung growth: Utilizing a VEGF inhibitor. PLoS One 2018; 13:e0208579. [PMID: 30566445 PMCID: PMC6300284 DOI: 10.1371/journal.pone.0208579] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Accepted: 11/20/2018] [Indexed: 12/11/2022] Open
Abstract
Exogenous vascular endothelial growth factor (VEGF) accelerates compensatory lung growth (CLG) in mice after unilateral pneumonectomy. In this study, we unexpectedly discovered a method to enhance CLG with a VEGF inhibitor, soluble VEGFR1. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily intraperitoneal (ip) injection of either saline (control) or 20 μg/kg of VEGFR1-Fc. On post-operative day (POD) 4, mice underwent pulmonary function tests (PFT) and lungs were harvested for volume measurement and analyses of the VEGF signaling pathway. To investigate the role of hypoxia in mediating the effects of VEGFR1, experiments were repeated with concurrent administration of PT-2385, an inhibitor of hypoxia-induced factor (HIF)2α, via orogastric gavage at 10 mg/kg every 12 hours for 4 days. We found that VEGFR1-treated mice had increased total lung capacity (P = 0.006), pulmonary compliance (P = 0.03), and post-euthanasia lung volume (P = 0.049) compared to control mice. VEGFR1 treatment increased pulmonary levels of VEGF (P = 0.008) and VEGFR2 (P = 0.01). It also stimulated endothelial proliferation (P < 0.0001) and enhanced pulmonary surfactant production (P = 0.03). The addition of PT-2385 abolished the increase in lung volume and endothelial proliferation in response to VEGFR1. By paradoxically stimulating angiogenesis and enhancing lung growth, VEGFR1 could represent a new treatment strategy for neonatal lung diseases characterized by dysfunction of the HIF-VEGF pathway.
Collapse
Affiliation(s)
- Duy T. Dao
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Lorenzo Anez-Bustillos
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Sahir S. Jabbouri
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Amy Pan
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Hiroko Kishikawa
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Paul D. Mitchell
- Institutional Centers for Clinical and Translational Research, Boston Children’s Hospital, Boston, MA, United States of America
| | - Gillian L. Fell
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Meredith A. Baker
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Randolph S. Watnick
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Hong Chen
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Michael S. Rogers
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Diane R. Bielenberg
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| | - Mark Puder
- Vascular Biology Program, Boston Children’s Hospital, Boston, MA, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, MA, United States of America
| |
Collapse
|
34
|
Wu H, Rahman HA, Dong Y, Liu X, Lee Y, Wen A, To KH, Xiao L, Birsner AE, Bazinet L, Wong S, Song K, Brophy ML, Mahamud MR, Chang B, Cai X, Pasula S, Kwak S, Yang W, Bischoff J, Xu J, Bielenberg DR, Dixon JB, D’Amato RJ, Srinivasan RS, Chen H. Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes. J Clin Invest 2018; 128:4025-4043. [PMID: 30102256 PMCID: PMC6118634 DOI: 10.1172/jci96063] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 06/26/2018] [Indexed: 12/18/2022] Open
Abstract
Impaired lymphangiogenesis is a complication of chronic complex diseases, including diabetes. VEGF-C/VEGFR3 signaling promotes lymphangiogenesis, but how this pathway is affected in diabetes remains poorly understood. We previously demonstrated that loss of epsins 1 and 2 in lymphatic endothelial cells (LECs) prevented VEGF-C-induced VEGFR3 from endocytosis and degradation. Here, we report that diabetes attenuated VEGF-C-induced lymphangiogenesis in corneal micropocket and Matrigel plug assays in WT mice but not in mice with inducible lymphatic-specific deficiency of epsins 1 and 2 (LEC-iDKO). Consistently, LECs isolated from diabetic LEC-iDKO mice elevated in vitro proliferation, migration, and tube formation in response to VEGF-C over diabetic WT mice. Mechanistically, ROS produced in diabetes induced c-Src-dependent but VEGF-C-independent VEGFR3 phosphorylation, and upregulated epsins through the activation of transcription factor AP-1. Augmented epsins bound to and promoted degradation of newly synthesized VEGFR3 in the Golgi, resulting in reduced availability of VEGFR3 at the cell surface. Preclinically, the loss of lymphatic-specific epsins alleviated insufficient lymphangiogenesis and accelerated the resolution of tail edema in diabetic mice. Collectively, our studies indicate that inhibiting expression of epsins in diabetes protects VEGFR3 against degradation and ameliorates diabetes-triggered inhibition of lymphangiogenesis, thereby providing a novel potential therapeutic strategy to treat diabetic complications.
Collapse
Affiliation(s)
- Hao Wu
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - H.N. Ashiqur Rahman
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Yunzhou Dong
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Xiaolei Liu
- Center for Vascular and Developmental Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Yang Lee
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Aiyun Wen
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Kim H.T. To
- Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Li Xiao
- Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Amy E. Birsner
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Lauren Bazinet
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Scott Wong
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Kai Song
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Megan L. Brophy
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
- Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
| | - M. Riaj Mahamud
- Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Baojun Chang
- Vascular Medicine Institute, Pulmonary, Allergy and Critical Care Division, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Xiaofeng Cai
- Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Satish Pasula
- Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Sukyoung Kwak
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Wenxia Yang
- Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Joyce Bischoff
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - Jian Xu
- Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
| | - Diane R. Bielenberg
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - J. Brandon Dixon
- Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA
| | - Robert J. D’Amato
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| | - R. Sathish Srinivasan
- Cardiovascular Biology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
| | - Hong Chen
- Vascular Biology Program, Harvard Medical School, Boston Children’s Hospital, Boston, Massachusetts, USA
| |
Collapse
|
35
|
Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW, Panigrahy D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J 2018; 33:114-125. [PMID: 29957058 PMCID: PMC6355061 DOI: 10.1096/fj.201800019rr] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Colon cancer recurrence after therapy, such as 5-fluorouracil (5-FU), remains a challenge in the clinical setting. Chemotherapy reduces tumor burden by inducing cell death; however, the resulting dead tumor cells, or debris, may paradoxically stimulate angiogenesis, inflammation, and tumor growth. Here, we demonstrate that 5-FU–generated colon carcinoma debris stimulates the growth of a subthreshold inoculum of living tumor cells in subcutaneous and orthotopic models. Debris triggered the release of osteopontin (OPN) by tumor cells and host macrophages. Both coinjection of debris and systemic treatment with 5-FU increased plasma OPN levels in tumor-bearing mice. RNA expression levels of secreted phosphoprotein 1, the gene that encodes OPN, correlate with poor prognosis in patients with colorectal cancer and are elevated in chemotherapy-treated patients who experience tumor recurrence vs. no recurrence. Pharmacologic and genetic ablation of OPN inhibited debris-stimulated tumor growth. Systemic treatment with a combination of a neutralizing OPN antibody and 5-FU dramatically inhibited tumor growth. These results demonstrate a novel mechanism of tumor progression mediated by OPN released in response to chemotherapy-generated tumor cell debris. Neutralization of debris-stimulated OPN represents a potential therapeutic strategy to overcome the inherent limitation of cytotoxic therapies as a result of the generation of cell debris.—Chang, J., Bhasin, S. S., Bielenberg, D. R., Sukhatme, V. P., Bhasin, M., Huang, S., Kieran, M. W., Panigrahy, D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.
Collapse
Affiliation(s)
- Jaimie Chang
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Swati S Bhasin
- Division of Interdisciplinary Medicine and Biology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.,Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
| | - Vikas P Sukhatme
- Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Manoj Bhasin
- Division of Interdisciplinary Medicine and Biology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Sui Huang
- Institute for Systems Biology, Seattle, Washington, USA
| | - Mark W Kieran
- Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Dipak Panigrahy
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
36
|
Dao DT, Anez-Bustillos L, Ourieff J, Pan A, Mitchell PD, Kishikawa H, Fell GL, Baker MA, Watnick RS, Chen H, Hamilton TE, Rogers MS, Bielenberg DR, Puder M. Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy. Angiogenesis 2018; 21:837-848. [PMID: 29956017 DOI: 10.1007/s10456-018-9628-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 06/26/2018] [Indexed: 12/24/2022]
Abstract
Children with hypoplastic lung diseases, such as congenital diaphragmatic hernia, can require life support via extracorporeal membrane oxygenation and systemic anticoagulation, usually in the form of heparin. The role of heparin in angiogenesis and organ growth is inconclusive, with conflicting data reported in the literature. This study aimed to investigate the effects of heparin on lung growth in a model of compensatory lung growth (CLG). Compared to the absence of heparin, treatment with heparin decreased the vascular endothelial growth factor (VEGF)-mediated activation of VEGFR2 and mitogenic effect on human lung microvascular endothelial cells in vitro. Compared to non-heparinized controls, heparinized mice demonstrated impaired pulmonary mechanics, decreased respiratory volumes and flows, and reduced activity levels after left pneumonectomy. They also had lower lung volume, pulmonary septal surface area and alveolar density on morphometric analyses. Lungs of heparinized mice displayed decreased phosphorylation of VEGFR2 compared to the control group, with consequential downstream reduction in markers of cellular proliferation and survival. The use of bivalirudin, an alternative anticoagulant that does not interact with VEGF, preserved lung growth and pulmonary mechanics. These results demonstrated that heparin impairs CLG by reducing VEGFR2 activation. These findings raise concern for the clinical use of heparin in the setting of organ growth or regeneration.
Collapse
Affiliation(s)
- Duy T Dao
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Lorenzo Anez-Bustillos
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Jared Ourieff
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Amy Pan
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Paul D Mitchell
- Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, 02115, USA
| | - Hiroko Kishikawa
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Gillian L Fell
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Meredith A Baker
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Randolph S Watnick
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Hong Chen
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Thomas E Hamilton
- Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Michael S Rogers
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA
| | - Mark Puder
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. .,Department of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA.
| |
Collapse
|
37
|
Dao DT, Vuong JT, Anez-Bustillos L, Pan A, Mitchell PD, Fell GL, Baker MA, Bielenberg DR, Puder M. Intranasal delivery of VEGF enhances compensatory lung growth in mice. PLoS One 2018; 13:e0198700. [PMID: 29879188 PMCID: PMC5991715 DOI: 10.1371/journal.pone.0198700] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Accepted: 05/23/2018] [Indexed: 01/04/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5-50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.
Collapse
Affiliation(s)
- Duy T. Dao
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Jacqueline T. Vuong
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Lorenzo Anez-Bustillos
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Amy Pan
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Paul D. Mitchell
- Institutional Centers for Clinical and Translational Research, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Gillian L. Fell
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Meredith A. Baker
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Diane R. Bielenberg
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| | - Mark Puder
- Vascular Biology Program, Boston Children’s Hospital, Boston, Massachusetts, United States of America
- Department of Surgery, Boston Children’s Hospital, Boston, Massachusetts, United States of America
| |
Collapse
|
38
|
Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, Greene ER, Gus-Brautbar Y, Piwowarski J, Mammoto T, Zurakowski D, Perretti M, Sukhatme VP, Kaipainen A, Kieran MW, Huang S, Panigrahy D. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 2017; 215:115-140. [PMID: 29191914 PMCID: PMC5748851 DOI: 10.1084/jem.20170681] [Citation(s) in RCA: 182] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 09/15/2017] [Accepted: 10/11/2017] [Indexed: 12/22/2022] Open
Abstract
Cancer therapy reduces tumor burden by killing tumor cells, yet it simultaneously creates tumor cell debris that may stimulate inflammation and tumor growth. Sulciner et al. demonstrate that specific resolvins (RvD1, RvD2, and RvE1) inhibit tumor growth and enhance cancer therapy through the clearance of tumor cell debris. Cancer therapy reduces tumor burden by killing tumor cells, yet it simultaneously creates tumor cell debris that may stimulate inflammation and tumor growth. Thus, conventional cancer therapy is inherently a double-edged sword. In this study, we show that tumor cells killed by chemotherapy or targeted therapy (“tumor cell debris”) stimulate primary tumor growth when coinjected with a subthreshold (nontumorigenic) inoculum of tumor cells by triggering macrophage proinflammatory cytokine release after phosphatidylserine exposure. Debris-stimulated tumors were inhibited by antiinflammatory and proresolving lipid autacoids, namely resolvin D1 (RvD1), RvD2, or RvE1. These mediators specifically inhibit debris-stimulated cancer progression by enhancing clearance of debris via macrophage phagocytosis in multiple tumor types. Resolvins counterregulate the release of cytokines/chemokines, including TNFα, IL-6, IL-8, CCL4, and CCL5, by human macrophages stimulated with cell debris. These results demonstrate that enhancing endogenous clearance of tumor cell debris is a new therapeutic target that may complement cytotoxic cancer therapies.
Collapse
Affiliation(s)
- Megan L Sulciner
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Charles N Serhan
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Molly M Gilligan
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Dayna K Mudge
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Jaimie Chang
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Allison Gartung
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Kristen A Lehner
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Birgitta Schmidt
- Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Jesmond Dalli
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Emily R Greene
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Yael Gus-Brautbar
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Julia Piwowarski
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Tadanori Mammoto
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - David Zurakowski
- Department of Anesthesia, Boston Children's Hospital, Harvard Medical School, Boston, MA.,Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Mauro Perretti
- The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, England, UK
| | - Vikas P Sukhatme
- Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Arja Kaipainen
- Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Mark W Kieran
- Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA .,Department of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Sui Huang
- Institute of Systems Biology, Seattle, WA
| | - Dipak Panigrahy
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA .,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| |
Collapse
|
39
|
Lam JD, Oh DJ, Wong LL, Amarnani D, Park-Windhol C, Sanchez AV, Cardona-Velez J, McGuone D, Stemmer-Rachamimov AO, Eliott D, Bielenberg DR, van Zyl T, Shen L, Gai X, D'Amore PA, Kim LA, Arboleda-Velasquez JF. Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis. Diabetes 2017; 66:1950-1956. [PMID: 28400392 PMCID: PMC5482092 DOI: 10.2337/db16-1035] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Accepted: 03/16/2017] [Indexed: 01/27/2023]
Abstract
Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed world's working adult population and affects those with type 1 and type 2 diabetes. We identified Runt-related transcription factor 1 (RUNX1) as a gene upregulated in CD31+ vascular endothelial cells obtained from human PDR fibrovascular membranes (FVMs) via transcriptomic analysis. In vitro studies using human retinal microvascular endothelial cells (HRMECs) showed increased RUNX1 RNA and protein expression in response to high glucose, whereas RUNX1 inhibition reduced HRMEC migration, proliferation, and tube formation. Immunohistochemical staining for RUNX1 showed reactivity in vessels of patient-derived FVMs and angiogenic tufts in the retina of mice with oxygen-induced retinopathy, suggesting that RUNX1 upregulation is a hallmark of aberrant retinal angiogenesis. Inhibition of RUNX1 activity with the Ro5-3335 small molecule resulted in a significant reduction of neovascular tufts in oxygen-induced retinopathy, supporting the feasibility of targeting RUNX1 in aberrant retinal angiogenesis.
Collapse
Affiliation(s)
- Jonathan D Lam
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Daniel J Oh
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Lindsay L Wong
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Dhanesh Amarnani
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Cindy Park-Windhol
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Angie V Sanchez
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Jonathan Cardona-Velez
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
- Universidad Pontificia Bolivariana, Medellin, Colombia
| | - Declan McGuone
- C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA
| | | | - Dean Eliott
- Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Diane R Bielenberg
- Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Tave van Zyl
- Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Lishuang Shen
- Center for Personalized Medicine, Children's Hospital Los Angeles, Los Angeles, CA
| | - Xiaowu Gai
- Center for Personalized Medicine, Children's Hospital Los Angeles, Los Angeles, CA
| | - Patricia A D'Amore
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
- Department of Pathology, Harvard Medical School, Boston, MA
| | - Leo A Kim
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
- Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| | - Joseph F Arboleda-Velasquez
- Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA
| |
Collapse
|
40
|
Guo P, Yang J, Bielenberg DR, Dillon D, Zurakowski D, Moses MA, Auguste DT. A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release 2017; 263:57-67. [PMID: 28341549 DOI: 10.1016/j.jconrel.2017.03.030] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 03/10/2017] [Accepted: 03/17/2017] [Indexed: 12/11/2022]
Abstract
Identifying a molecular target is essential for tumor-targeted nanomedicine. Current cancer nanomedicines commonly suffer from poor tumor specificity, "off-target" toxicity, and limited clinical efficacy. Here, we report a method to screen and identify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis. In our proof-of-principle study, we used comparative flow cytometric screening to identify ICAM-1 as a potential target for metastatic melanoma (MM). We further evaluated ICAM-1 as a MM targeting moiety by characterizing its (1) tumor specificity, (2) expression level, (3) cellular internalization, (4) therapeutic function, and (5) potential clinical impact. Quantitation of ICAM-1 protein expression on cells and validation by immunohistochemistry on human tissue specimens justified the synthesis of antibody-functionalized drug delivery vehicles, which were benchmarked against appropriate controls. We engineered ICAM-1 antibody conjugated, doxorubicin encapsulating immunoliposomes (ICAM-Dox-LPs) to selectively recognize and deliver doxorubicin to MM cells and simultaneously neutralize ICAM-1 signaling via an antibody blockade, demonstrating significant and simultaneous inhibitory effects on MM cell proliferation and migration. This paper describes a novel, quantitative metric system that identifies and evaluates new cancer targets for tumor-targeting nanomedicine.
Collapse
Affiliation(s)
- Peng Guo
- Department of Biomedical Engineering, The City College of New York, 160 Convent Avenue, New York, NY 10031, United States; Vascular Biology Program, Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115, United States; Department of Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States
| | - Jiang Yang
- Vascular Biology Program, Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115, United States; Department of Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115, United States; Department of Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States
| | - Deborah Dillon
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States
| | - David Zurakowski
- Department of Anesthesia, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States
| | - Marsha A Moses
- Vascular Biology Program, Boston Children's Hospital, 1 Blackfan Circle, Boston, MA 02115, United States; Department of Surgery, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, United States
| | - Debra T Auguste
- Department of Biomedical Engineering, The City College of New York, 160 Convent Avenue, New York, NY 10031, United States.
| |
Collapse
|
41
|
Vasquez E, Cristofaro V, Lukianov S, Burkhard FC, Gheinani AH, Monastyrskaya K, Bielenberg DR, Sullivan MP, Adam RM. Deletion of neuropilin 2 enhances detrusor contractility following bladder outlet obstruction. JCI Insight 2017; 2:e90617. [PMID: 28194441 DOI: 10.1172/jci.insight.90617] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Chronic urethral obstruction and the ensuing bladder wall remodeling can lead to diminished bladder smooth muscle (BSM) contractility and debilitating lower urinary tract symptoms. No effective pharmacotherapy exists to restore BSM contractile function. Neuropilin 2 (Nrp2) is a transmembrane protein that is highly expressed in BSM. Nrp2 deletion in mice leads to increased BSM contraction. We determined whether genetic ablation of Nrp2 could restore BSM contractility following obstruction. Partial bladder outlet obstruction (pBOO) was created by urethral occlusion in mice with either constitutive and ubiquitous, or inducible smooth muscle-specific deletion of Nrp2, and Nrp2-intact littermates. Mice without obstruction served as additional controls. Contractility was measured by isometric tension testing. Nrp2 deletion prior to pBOO increased force generation in BSM 4 weeks following surgery. Deletion of Nrp2 in mice already subjected to pBOO for 4 weeks showed increased contractility of tissues tested 6 weeks after surgery compared with nondeleted controls. Assessment of tissues from patients with urodynamically defined bladder outlet obstruction revealed reduced NRP2 levels in obstructed bladders with compensated compared with decompensated function, relative to asymptomatic controls. We conclude that downregulation of Nrp2 promotes BSM force generation. Neuropilin 2 may represent a novel target to restore contractility following obstruction.
Collapse
Affiliation(s)
- Evalynn Vasquez
- Urological Diseases Research Center, Boston Children's Hospital.,Department of Surgery, Harvard Medical School
| | - Vivian Cristofaro
- Department of Surgery, Harvard Medical School.,Division of Urology, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA
| | - Stefan Lukianov
- Urological Diseases Research Center, Boston Children's Hospital
| | - Fiona C Burkhard
- Urology Research Laboratory, Department of Clinical Research, Universität Bern, Bern, Switzerland
| | - Ali Hashemi Gheinani
- Urology Research Laboratory, Department of Clinical Research, Universität Bern, Bern, Switzerland
| | - Katia Monastyrskaya
- Urology Research Laboratory, Department of Clinical Research, Universität Bern, Bern, Switzerland
| | - Diane R Bielenberg
- Department of Surgery, Harvard Medical School.,Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Maryrose P Sullivan
- Department of Surgery, Harvard Medical School.,Division of Urology, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA
| | - Rosalyn M Adam
- Urological Diseases Research Center, Boston Children's Hospital.,Department of Surgery, Harvard Medical School
| |
Collapse
|
42
|
Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med 2016; 8:329ra34. [PMID: 26962158 DOI: 10.1126/scitranslmed.aad5653] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The vast majority of ovarian cancer-related deaths are caused by metastatic dissemination of tumor cells, resulting in subsequent organ failure. However, despite our increased understanding of the physiological processes involved in tumor metastasis, there are no clinically approved drugs that have made a major impact in increasing the overall survival of patients with advanced, metastatic ovarian cancer. We identified prosaposin (psap) as a potent inhibitor of tumor metastasis, which acts via stimulation of p53 and the antitumorigenic protein thrombospondin-1 (TSP-1) in bone marrow-derived cells that are recruited to metastatic sites. We report that more than 97% of human serous ovarian tumors tested express CD36, the receptor that mediates the proapoptotic activity of TSP-1. Accordingly, we sought to determine whether a peptide derived from psap would be effective in treating this form of ovarian cancer. To that end, we developed a cyclic peptide with drug-like properties derived from the active sequence in psap. The cyclic psap peptide promoted tumor regression in a patient-derived tumor xenograft model of metastatic ovarian cancer. Thus, we hypothesize that a therapeutic agent based on this psap peptide would have efficacy in treating patients with metastatic ovarian cancer.
Collapse
Affiliation(s)
- Suming Wang
- Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115, USA. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
| | - Anna Blois
- Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115, USA. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA. Centre for Cancer Biomarkers (CCBIO), Department of Clinical Medicine, University of Bergen, NO-5020 Bergen, Norway
| | - Tina El Rayes
- Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY 10065, USA. Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10065, USA. Neuberger Berman Lung Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
| | - Joyce F Liu
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
| | - Michelle S Hirsch
- Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
| | - Karsten Gravdal
- Centre for Cancer Biomarkers (CCBIO), Department of Clinical Medicine, University of Bergen, NO-5020 Bergen, Norway. Department of Pathology, Haukeland University Hospital, N-5021 Bergen, Norway
| | - Sangeetha Palakurthi
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115, USA. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
| | - Lars A Akslen
- Centre for Cancer Biomarkers (CCBIO), Department of Clinical Medicine, University of Bergen, NO-5020 Bergen, Norway. Department of Pathology, Haukeland University Hospital, N-5021 Bergen, Norway
| | - Ronny Drapkin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
| | - Vivek Mittal
- Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY 10065, USA. Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY 10065, USA. Neuberger Berman Lung Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
| | - Randolph S Watnick
- Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115, USA. Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
| |
Collapse
|
43
|
Mucka P, Levonyak N, Geretti E, Zwaans BMM, Li X, Adini I, Klagsbrun M, Adam RM, Bielenberg DR. Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency. Am J Pathol 2016; 186:2803-2812. [PMID: 27751443 DOI: 10.1016/j.ajpath.2016.07.022] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Revised: 07/10/2016] [Accepted: 07/14/2016] [Indexed: 12/20/2022]
Abstract
The vasculature influences the progression and resolution of tissue inflammation. Capillaries express vascular endothelial growth factor (VEGF) receptors, including neuropilins (NRPs), which regulate interstitial fluid flow. NRP2, a receptor of VEGFA and semaphorin (SEMA) 3F ligands, is expressed in the vascular and lymphatic endothelia. Previous studies have demonstrated that blocking VEGF receptor 2 attenuates VEGFA-induced vascular permeability. The inhibition of NRP2 was hypothesized to decrease vascular permeability as well. Unexpectedly, massive tissue swelling and edema were observed in Nrp2-/- mice compared with wild-type littermates after delayed-type hypersensitivity reactions. Vascular permeability was twofold greater in inflamed blood vessels in Nrp2-deficient mice compared to those in Nrp2-intact littermates. The addition of exogenous SEMA3F protein inhibited vascular permeability in Balb/cJ mice, suggesting that the loss of endogenous Sema3F activity in the Nrp2-deficient mice was responsible for the enhanced vessel leakage. Functional lymphatic capillaries are necessary for draining excess fluid after inflammation; however, Nrp2-mutant mice lacked superficial lymphatic capillaries, leading to 2.5-fold greater fluid retention and severe lymphedema after inflammation. In conclusion, Nrp2 deficiency increased blood vessel permeability and decreased lymphatic vessel drainage during inflammation, highlighting the importance of the NRP2/SEMA3F pathway in the modulation of tissue swelling and resolution of postinflammatory edema.
Collapse
Affiliation(s)
- Patrick Mucka
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts
| | - Nicholas Levonyak
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts
| | - Elena Geretti
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts
| | | | - Xiaoran Li
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts
| | - Irit Adini
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts
| | - Michael Klagsbrun
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts
| | - Rosalyn M Adam
- Department of Surgery, Harvard Medical School, Boston, Massachusetts; Urological Diseases Research Center, Boston Children's Hospital, Boston, Massachusetts
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
44
|
Song K, Wu H, Rahman HNA, Dong Y, Wen A, Brophy ML, Wong S, Kwak S, Bielenberg DR, Chen H. Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis. Cell Mol Life Sci 2016; 74:393-398. [PMID: 27572288 DOI: 10.1007/s00018-016-2347-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 08/17/2016] [Accepted: 08/22/2016] [Indexed: 12/16/2022]
Abstract
VEGF-driven tumor angiogenesis has been validated as a central target in several tumor types deserving of continuous and further considerations to improve the efficacy and selectivity of the current therapeutic paradigms. Epsins, a family of endocytic clathrin adaptors, have been implicated in regulating endothelial cell VEGFR2 signaling, where its inactivation leads to nonproductive leaky neo-angiogenesis and, therefore, impedes tumor development and progression. Targeting endothelial epsins is of special significance due to its lack of affecting other angiogenic-signaling pathways or disrupting normal quiescent vessels, suggesting a selective modulation of tumor angiogenesis. This review highlights seminal findings on the critical role of endothelial epsins in tumor angiogenesis and their underlying molecular events, as well as strategies to prohibit the normal function of endogenous endothelial epsins that capitalize on these newly understood mechanisms.
Collapse
Affiliation(s)
- Kai Song
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Hao Wu
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - H N Ashiqur Rahman
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Yunzhou Dong
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Aiyun Wen
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Megan L Brophy
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Scott Wong
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Sukyoung Kwak
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA
| | - Hong Chen
- Vascular Biology Program, Karp Family Research Laboratory, Department of Surgery, Boston Children's Hospital, Harvard Medical School, 12.214, 300 Longwood Avenue, Boston, MA, 02115, USA.
| |
Collapse
|
45
|
Wong LL, Lee NG, Amarnani D, Choi CJ, Bielenberg DR, Freitag SK, D'Amore PA, Kim LA. Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation. Ophthalmology 2016; 123:2028-36. [PMID: 27423310 DOI: 10.1016/j.ophtha.2016.05.052] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Revised: 05/31/2016] [Accepted: 05/31/2016] [Indexed: 01/12/2023] Open
Abstract
PURPOSE The human orbit is an environment that is vulnerable to inflammation and edema in the setting of autoimmune thyroid disease. Our study investigated the tenet that orbital adipose tissue lacks lymphatic vessels and analyzed the clinicopathologic differences between patients with acute and chronic thyroid eye disease (TED). The underlying molecular mediators of blood and lymphatic vessel formation within the orbital fat also were evaluated. DESIGN Retrospective cohort study. PARTICIPANTS The study included fat specimens from 26 orbits of 15 patients with TED undergoing orbital decompression. Orbital fat specimens from patients without TED as well as cadaveric orbital fat served as controls. METHODS Tissue specimens were processed as formalin-fixed, paraffin-embedded sections or frozen cryosections for immunohistochemistry. Total RNA was extracted and analyzed via quantitative (real-time) reverse-transcription polymerase chain reaction. Clinicopathologic correlation was made by determining the clinical activity score (CAS) of each patient with TED. MAIN OUTCOME MEASURES Samples were examined for vascular and lymphatic markers including podoplanin, lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and cluster of differentiation 31 (CD31) by immunohistochemistry, as well as for mRNA levels of vascular endothelial growth factor (VEGF), VEGF receptors, semaphorin 3F, neuropilin 1, neuropilin 2, podoplanin, and LYVE-1 by quantitative (real-time) reverse-transcription polymerase chain reaction. RESULTS Clinicopathologic correlation revealed increased staining of CD31-positive blood vessels in patients with acute TED with a CAS more than 4, as well as rare staining of podoplanin-positive lymphatic vessels within acutely inflamed orbital fat tissue. Additionally, quantitative (real-time) reverse-transcription polymerase chain reaction analysis demonstrated increased expression of VEGF receptor (VEGFR) 2 as well as VEGF signaling molecules VEGF-A, VEGF-C, and VEGF-D. CONCLUSIONS In acute TED, compared with chronic TED and control orbital fat, there is increased blood vessel density, suggesting neovascularization and rare lymphatic vessels suggestive of limited lymphangiogenesis. This proangiogenic and prolymphangiogenic microenvironment is likely the result of the increased expression of VEGFR-2, VEGF-A, VEGF-C, and VEGF-D. These findings imply that orbital edema in acute TED may be mediated, in part, by both the formation of new, immature blood vessels and the formation of lymphatic capillaries that are functionally incapable of draining interstitial fluid.
Collapse
Affiliation(s)
- Lindsay L Wong
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| | - Nahyoung Grace Lee
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| | - Dhanesh Amarnani
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| | - Catherine J Choi
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| | - Diane R Bielenberg
- Department of Surgery, Harvard Medical School, Children's Hospital of Boston, Boston, Massachusetts
| | - Suzanne K Freitag
- Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Ophthalmic Plastic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
| | - Patricia A D'Amore
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
| | - Leo A Kim
- Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
46
|
Migliozzi M, Hida Y, Seth M, Brown G, Kwan J, Coma S, Panigrahy D, Adam RM, Banyard J, Shimizu A, R. Bielenberg D. VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells. ACTA ACUST UNITED AC 2015. [DOI: 10.2174/221155280304150825120419] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
47
|
Abstract
Metastatic cancer cells are lethal. Understanding the molecular mechanisms that bolster the conversion from benign to malignant progression is key for treating these heterogeneous and resistant neoplasms. The epithelial-mesenchymal transition (EMT) is a conserved cellular program that alters cell shape, adhesion and movement. The shift to a more mesenchymal-like phenotype can promote tumor cell intravasation of surrounding blood vessels and emigration to a new organ, yet may not be necessary for extravasation or colonization into that environment. Lymphatic dissemination, on the other hand, may not require EMT. This review presents emerging data on the modes by which tumor cells promote EMT/MET via microRNA and prepare the pre-metastatic niche via exosomes.
Collapse
Affiliation(s)
- Jacqueline Banyard
- a Vascular Biology Program, Department of Surgery , Boston Children's Hospital, Harvard Medical School , Boston , MA , USA
| | - Diane R Bielenberg
- a Vascular Biology Program, Department of Surgery , Boston Children's Hospital, Harvard Medical School , Boston , MA , USA
| |
Collapse
|
48
|
Adini I, Adini A, Bazinet L, Watnick RS, Bielenberg DR, D'Amato RJ. Melanocyte pigmentation inversely correlates with MCP-1 production and angiogenesis-inducing potential. FASEB J 2014; 29:662-70. [PMID: 25406462 DOI: 10.1096/fj.14-255398] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The incidence of certain angiogenesis-dependent diseases is higher in Caucasians than in African Americans. Angiogenesis is amplified in wound healing and cornea models in albino C57 mice compared with black C57 mice. Moreover, mouse and human melanocytes with low pigmentation stimulate endothelial cell (EC) proliferation and migration in vitro more than melanocytes with high pigmentation. This effect is due, in part, to the secretion of an angiogenic protein called fibromodulin (FMOD) from lowly pigmented melanocytes. Herein, we expand upon the mechanism contributing to increased angiogenesis in lighter skin and report that monocyte chemotactic protein-1 (MCP-1) is secreted by nonpigmented mouse melanocytes by 5- to 10-fold more than pigmented melanocytes. MCP-1 protein stimulates EC proliferation and migration in vitro and angiogenesis in vivo. Mechanistic studies determine that FMOD is upstream of MCP-1 and promotes its secretion from both melanocytes and activated ECs via stimulation of NF-κB activity. Mice injected with FMOD-neutralizing antibodies show 2.3-fold decreased levels of circulating MCP-1. Human studies confirmed that, on average, Caucasians have 2-fold higher serum levels of MCP-1 than African Americans. Taken together, this study implicates the FMOD/MCP-1 pathway in the regulation of angiogenesis by local melanocytes and suggests that melanogenic activity may protect against aberrant angiogenic diseases.
Collapse
Affiliation(s)
- Irit Adini
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Avner Adini
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Lauren Bazinet
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Randolph S Watnick
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Robert J D'Amato
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
49
|
Sulciner ML, Mudge DK, Bielenberg DR, Benny O, Dalli J, Huang S, Serhan CN, Kieran MW, Panigrahy D. Abstract 1664: Cancer progression: The failure to resolve. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-1664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Failure to resolve inflammation contributes to disease pathogenesis. Inflammation in the tumor microenvironment is now recognized as one of the hallmarks of cancer. Anti-inflammatory therapies have focused on suppressing pro-inflammatory mediators, cytokines and eicosanoids. However, a new direction has emerged with the discovery of a novel genus of endogenous anti-inflammatory and pro-resolving lipid-autacoid mediators derived from omega-3 polyunsaturated fatty acids, specifically resolvins (Rvs). Resolvins have potent novel inflammation clearing (pro-resolution) activity without being immunosuppressive and are also anti-inflammatory, anti-angiogenic, anti-infective and anti-fibrotic. We hypothesize the failure of the resolution of inflammation can lead to cancer progression and resolvins inhibit tumor progression and metastasis. Results: Resolvins potently inhibited primary tumor growth in subcutaneous, orthotopic and genetically engineered models of cancer. After primary tumor resection, resolvins suppressed spontaneous lung metastasis. Resolvins prevent apoptosis-stimulated tumor growth (Révész effect) without toxicity by stimulating the resolution of inflammation at nanogram levels (at doses over 10,000 fold less than aspirin or omega-3 fatty acids). Resolvins (RvD1, RvD2, and RvE1) activated human macrophage phagocytosis of apoptotic human tumor cells (including prostate and ovarian), which was reversed with a lipoxygenase inhibitor (baicalein). Similarly, RvD1 stimulated murine macrophage phagocytosis of chemotherapy-induced apoptotic murine tumor cells (including ovarian), which was reversed by the ALX/FPR-2 selective antagonist BOC-1. Resolvins also counter-regulated chemotherapy-induced pro-inflammatory cytokines/chemokines including TNFα, IL-6, IL-8, CCL4 and CCL5. Furthermore, resolvins reduced leukocyte infiltration and VEGF-dependent tumor angiogenesis. Resolvins induce a new phenotype of tumor-associated macrophages that are M2-like (increased CD206+/F4/80+), but possess phagocytic activity (CD11bhigh/F4/80+). Electron microscopy confirmed phagocytosis of tumor cells in macrophages in RvD2-treated tumors. Depletion of macrophages promoted tumor growth in resolvin-treated mice. Resolvins display synergistic anti-tumor activity with the chemotherapeutic agent cisplatin to regress established primary tumors. The expression of the RvD1 receptor, ALX/FPR-2, decreased with spontaneous tumor (TRAMP) progression. Thus, cancer progression may be associated with the loss of an endogenous anti-inflammatory lipid mediator. Conclusions: Resolvins suppress primary tumor growth and metastasis via the stimulation of the uptake of apoptotic tumor cells by macrophages. The resolvin pathway, or the enhancement of endogenous resolution processes, therefore offers an entirely novel approach for controlling chronic inflammation as a modality of cancer treatment.
Citation Format: Megan L. Sulciner, Dayna K. Mudge, Diane R. Bielenberg, Ofra Benny, Jesmond Dalli, Sui Huang, Charles N. Serhan, Mark W. Kieran, Dipak Panigrahy. Cancer progression: The failure to resolve. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1664. doi:10.1158/1538-7445.AM2014-1664
Collapse
Affiliation(s)
| | | | | | | | | | - Sui Huang
- 4Institute for Systems Biology, Seattle, WA
| | | | | | | |
Collapse
|
50
|
Gus-Brautbar Y, Casper J, Bielenberg DR, Cheng J, Schmidt B, Hammock BD, Zeldin DC, Kieran MW, Panigrahy D. Abstract 4833: The eicosanoid 20-HETE triggers Ras activation, pancreatic cancer growth and metastasis through inflammatory macrophage signaling. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-4833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prolonged, unresolving inflammation is increasingly implicated in the pathogenesis of pancreatic cancer, but the critical inflammatory mediators remain largely unknown. Most efforts to elucidate these mediators have focused on protein cytokines rather than lipid autacoids. Lipid autacoids are metabolites of arachidonic acid and other related fatty acids that regulate inflammation and tumor growth. Among these, the metabolites of the cytochrome P450 (CYP) epoxygenases and ω-hydroxylases, including EETs and 20-HETE, respectively, have been largely neglected in cancer. Recently, we showed that epoxyeicosatrienoic acids (EETs) stimulate multi-organ metastasis and tumor dormancy escape. We report for the first time, that elevated levels of 20-hydroxyeicosatetraenoic acid (20-HETE), a product of the ω-hydroxylases CYP4A/F, stimulate primary pancreatic tumor growth and metastasis. Using genetic and pharmacological manipulation of endogenous 20-HETE, we demonstrate that systemic administration of 20-HETE promotes primary human and murine pancreatic cancer in subcutaneous and orthotopic models. Furthermore, a transgenic murine model of endogenously high 20-HETE level (Tie2-CYP4F2 Tr), exhibited spontaneous liver and mediastinal lymph node metastasis after resection of subcutaneous primary pancreatic tumors. In contrast, wild-type mice did not develop liver and mediastinal lymph node metastasis after primary tumor resection. We show that 20-HETE activated Ras in human pancreatic tumor cell lines and the 20-HETE antagonist, HET0016, decreased Ras activity. The p65 subunit of NF-κB also increased in a 20-HETE-dependent manner in these tumor cell lines. 20-HETE induced migration of human macrophages in vitro, and tumor-associated macrophages expressed the 20-HETE generating enzyme CYP4F2. Depletion of macrophages with clodronate liposomes impaired CYP-metabolite-stimulated tumor growth. In addition, we show that 14,15-EET promotes pancreatic tumor growth in vivo. Moreover, inhibitors of soluble epoxide hydrolase, the enzyme that metabolizes EETs, elevated EET levels and promoted pancreatic tumor growth. Either the 20-HETE antagonist HET0016, or the EET antagonist 14,15-EEZE alone significantly inhibited primary tumor growth. Remarkably, systemic administration of both antagonists together resulted in sustained regression of established pancreatic tumors. This combination of 20-HETE and EET antagonists also suppressed ascites formation and prolonged survival in an orthotopic pancreatic cancer model without toxic effects. Thus, 20-HETE and EET production by macrophages in the tumor microenvironment critically regulates Ras activation, pancreatic tumor growth and metastasis. Our studies offer a mechanistic rationale for using 20-HETE and EET antagonists as a novel approach and anti-cancer therapeutics for pancreatic cancer.
Citation Format: Yael Gus-Brautbar, Jessica Casper, Diane R. Bielenberg, Jennifer Cheng, Birgitta Schmidt, Bruce D. Hammock, Darryl C. Zeldin, Mark W. Kieran, Dipak Panigrahy. The eicosanoid 20-HETE triggers Ras activation, pancreatic cancer growth and metastasis through inflammatory macrophage signaling. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4833. doi:10.1158/1538-7445.AM2014-4833
Collapse
Affiliation(s)
- Yael Gus-Brautbar
- 1Center for Vascular Biology Research and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Jessica Casper
- 1Center for Vascular Biology Research and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Diane R. Bielenberg
- 2Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Jennifer Cheng
- 3Laboratory of Respiratory Biology, NIH-NIEHS, Research Triangle Park, NC
| | - Birgitta Schmidt
- 4Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA
| | - Bruce D. Hammock
- 5Department of Entomology and Cancer Research Center, UC-Davis, Davis, CA
| | - Darryl C. Zeldin
- 3Laboratory of Respiratory Biology, NIH-NIEHS, Research Triangle Park, NC
| | - Mark W. Kieran
- 6Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Dipak Panigrahy
- 1Center for Vascular Biology Research and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| |
Collapse
|